Dataset from A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours

This is a multicenter, randomized and open-label Phase II study to compare the safety,
tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro®
in high risk PCI patients.

Patients will receive standard treatment with acetylsalicylic acid (ASA) plus clopidogrel and
heparin. Eligible patients will be randomly assigned to receive open-label study treatment
with either ALX-0081 or ReoPro®. Patients will be stratified according to PCI type (elective
or ad-hoc) and stent type (bare metal stent or drug eluting stent).